Clinical Lab Products
  • Diagnostic Technologies
    • Anatomic Pathology
    • Clinical Chemistry
    • Digital Pathology
    • Flow Cytometry
    • Hematology & Serology
    • Immunoassay
    • Mass Spectrometry
    • Microbiology
    • Molecular Diagnostics
    • Point-of-Care
    • Urinalysis & Toxicology
  • Lab Products
    • Biochemicals & Chemical Reagents
    • Information Technology
    • Lab Automation
    • Lab Equipment
    • Lab Safety
    • Labware & Consumables
    • Quality Systems
  • Disease States
    • Allergy & Autoimmune
    • Cancer
    • Cardiovascular
    • Cerebrovascular
    • Dementias & Alzheimer’s
    • Diabetes & Metabolic Diseases
    • Infectious Diseases
    • Kidney Disease
    • Respiratory Disease
    • Sepsis
    • Womens Health
  • Lab Management
    • Accreditation
    • Company News
    • Compliance
    • Proficiency Testing
    • Resource Center
  • Resources
    • Podcasts
    • Webcasts
    • White Papers
    • Videos
  • Edition Archive

Select Page

Tag: Personalis

All

Latest
Personalis Data Highlights Early Cancer Recurrence Detection

Personalis Data Highlights Early Cancer Recurrence Detection

Clinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.

  • Medicare Expands Coverage for Cancer Immunotherapy Monitoring Test

  • Ultrasensitive ctDNA Test Outperforms Standard Metrics in Predicting Breast Cancer Outcomes After Neoadjuvant Therapy

  • Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance

  • What Clinical Lab Leaders Predict for 2026

  • Ultrasensitive ctDNA Test Shows Promise for Lung Cancer Monitoring

  • Medicare Covers Ultrasensitive MRD Test for Breast Cancer Surveillance

  • Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial

  • Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

  • PREDICT DNA and SCANDARE Study Results Unveiled

All

Latest
Risk of Lung Cancer Recurrence Linked to ctDNA Levels

Risk of Lung Cancer Recurrence Linked to ctDNA Levels

A new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer.

  • Whole Genome-Based Liquid Biopsy Assay Commercialization,  Collaboration Commences 

    Whole Genome-Based Liquid Biopsy Assay Commercialization, Collaboration Commences 

  • Personalis Gets Medicare Coverage for Genomic Tumor Profiling Assay

    Personalis Gets Medicare Coverage for Genomic Tumor Profiling Assay

  • Personalis and Tempus Collaborate to Advance Cancer Testing

    Personalis and Tempus Collaborate to Advance Cancer Testing

  • Personalis’ MRD Assay Detects ctDNA in Lung Cancer Patients Earlier

    Personalis’ MRD Assay Detects ctDNA in Lung Cancer Patients Earlier

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found

Clinical Lab Products

7300 W 110th St – Floor 7
Overland Park, KS 66210
(913) 955-2600

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Press Releases

Key Resources

Podcasts

Webinars

White Papers

Videos

Helpful Links

Media Solutions Kit

Subscribe Now

Contact Us

Submit an Article

  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2024 MEDQOR LLC. All Rights Reserved

✖